Introduction:Psoriasis is a chronic immune-mediated inflammatory skin disease increasingly recognized as a systemic disorder. Irisin, a circulating myokine, has recently emerged as a potential biomarker in inflammatory conditions.
Aim:To evaluate the role of irisin in psoriasis and its association with disease severity and treatment response.
Method:A systematic review was conducted by searching PubMed, Scopus, Web of Science, and Google Scholar for clinical studies published between 2015 and 2025 that assessed circulating irisin levels in patients with psoriasis. Studies meeting the inclusion criteria were included in the qualitative synthesis.
Results:Four eligible studies were included. Patients with chronic plaque psoriasis consistently demonstrated higher serum irisin levels compared with healthy controls. Positive correlations were observed between irisin concentrations and Psoriasis Area and Severity Index (PASI) scores. Furthermore, irisin levels decreased following systemic therapy, particularly methotrexate, in parallel with clinical improvement.
Conclusion :Irisin may reflect inflammatory disease activity in psoriasis and could serve as a non-invasive biomarker for assessing disease severity and monitoring treatment response.